ITP Australia delivers a number of recommendations to improve treatment access for patients living with Immune Thrombocytopenia.
ITP Australia delivers a number of recommendations to improve treatment access for patients living with Immune Thrombocytopenia.
At around this time each year in Australia, many ITP patients ask their primary care professional, whether it’s their GP or haematologist if they should be getting the annual influenza vaccine and there are always varying responses.
Dr Robert Bird, member of our Medical Advisory Board, has shared information about ITP patients being at an increased risk of blood clots and not just bleeding.
Delivered in February 2020, the National Strategic Action Plan is the first national and coordinated plan to help deliver better outcomes for more than the estimated 2 million Australians living with a rare disease.
Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans.
On 30 January 2020, the WHO Director-General declared the novel coronavirus (2019-nCoV) outbreak a public health emergency of international concern.
Included in the following article is the recently published and updated International Consensus Report for the investigation, treatment and management of Immune Thrombocytopenia (ITP) in all patients.
Many patients who have ITP have either undergone a splenectomy, or it’s part of the discussion around treatment. If you’re in Victoria, Tasmania and Queensland, you are added to their register to receive regular updates and information. Check out what their latest Health Update has to say.